HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Breast Cancer Research and Treatment

Volumn 86, Issue 3, 2004, Pages 197-206

  Di Leo, A ^a   Chan, S ^b   Paesmans, M ^a   Friedrichs, K ^c   Pinter, T ^d   Cocquyt, V ^e   Murray, E ^f   Bodrogi, I ^g   Walpole, E ^h   Lesperance, B ⁱ   Korec, S ^j   Crown, J ^k   Simmonds, P ^l   Von Minckwitz, G ^m   Leroy, J Y ^a   Durbecq, V ^a   Isola, J ⁿ   Aapro, M ^o   Piccart, M J ^a   Larsimont, D ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Petz Aladar Country Hospital   (Hungary)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^h PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^j CANCER RESEARCH INSTITUTE   (Slovakia)

^k ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^l SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^m Zentrum der Frauenheilkunde   (Germany)

ⁿ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^o Centre Anticancéreux   (Switzerland)

more..

Author keywords

c erb B 2; p 53; topoisomerase II alpha

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAMPLING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 4043131642     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000036783.88387.47     Document Type: Article

References (26)

1. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999
2. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Orbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999
3. Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, Chan S, Tang SC, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunel E, Hatteville L, Azli N, Nabholtz JM: Final results of the phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first-line chemotherapy for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 21: 35a, 2002 (abstr no 137)
4. Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Bezwoda WR, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P: A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 18: 127a, 1999 (abstr no 485)
5. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C, Riva A: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21: 36a, 2002 (abstr no 141)
6. Di Leo A, Larsimont D, Gancberg D, Ferreira-Filho AF, Cardoso F, Piccart MJ: Predictive molecular markers: a new window of opportunity in the adjuvant therapy of breast cancer. In: Nabholtz JM, Tonkin K, Aapro MS, Buzdar AU (eds) Breast Cancer Management. Martin Dunitz, London, UK, 2000, pp 429-439
7. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: Erb B-2, p-53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
8. Park S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erb B-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998
9. Park S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N: HER-2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92: 1991-1998, 2000
10. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan C, Ries F, Gobert P, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ: HER-2 and topo-isomerase II α as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12: 1081-1089, 2001
11. Moliterni A, Menard S, Valagussa P, Biganzoli E, Boracchi P, Marubini E, Pilotti S, Bonadonna G: HER-2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer. Proc Am Soc Clin Oncol 20: 23a, 2001 (abstr no 89)
12. Pritchard KI, O'Malley FA, Andrulis I, Shepherd LE, Tu D, Levine MN, Bramwell VHC: Prognostic and predictive value of HER-2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer. Proc Am Soc Clin Oncol 21: 42a, 2002 (abstr no 165)
13. Konecny G, Thomssen C, Pegram M, Luck H, Untch M, Pauletti G, Dandekar U, Ramos L, Kuhn W, Eidtmann H, Dubois A, Olbricht S, Steinfeld D, Moebus V, von Minckwitz G, Slamon D: HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 20: 23a, 2001 (abstr no 88)
14. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
15. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-1043, 2002
16. Tanner M, Jarvinen P, Isola J: Amplification of HER-2/neu and topoisomerase II α in primary and metastatic breast cancer. Cancer Res 61: 5345-5348, 2001
17. Namer M, Ettore F, Birtwhisle-Peyrottes I, Hartmann M, Hery M, Teissier E, Ferrero J, Largiller R: Comparison of c-erb-B2 expression in 104 primary breast tumors and their metastases by two immunohistochemical tests. Proc Am Soc Clin Oncol 19: 653a, 2000 (abstr no 2577)
18. Lower EE, Yassin R, Bleau R, Heffelfinger SC: HER-2/neu expression in primary breast cancer correlates with metastatic disease expression. Proc Am Soc Clin Oncol 20: 425a, 2001 (abstr no 1697)
19. Edgerton SM, Merkel DE, Moore DH, Thor AD: HER-2/neu/Erb B-2 status by immunohistochemistry and FISH: clonality and progression with recurrence and metastases. Breast Cancer Res Treat 64: 55, 2000 (abstr no 180)
20. Järvinen TAH, Tanner M, Rantonen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and deletion of topoisomerase II α associate with Erb B-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847, 2000
21. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ: HER-2 amplification and toposisomerase II α gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate and 5-fluorouracil. Clin Cancer Res 8: 1107-1116, 2002
22. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botsein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA: 10869-10874, 2001
23. O'Connor PM, Jackman J, Bal I, Myers TG, Fan S, Mutch M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997
24. Lowe SW, Bodis S, Mc Clatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994
25. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814, 1996
26. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T: p-53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 94: 9679-9683, 1997